R2 in the Treatment of Follicular Lymphoma
Lenalidomide Based Immunotherapy in the Treatment of FL
Follicular Lymphoma
DRUG: Revlimid
CR, Complete response rate, 12 weeks
PFS, Progression free survival rate, 1 year|OS, Overall survival rate, 1 year|ORR, Overall response rate, 12 weeks
Lenalidomide Based Immunotherapy efficacy related molecular biomarker in follicular lymphoma